The Centre caps trade margins on non-scheduled cancer drugs at 30%, potentially cutting prices by up to 70% and saving patients ₹2,500 crore annually.
The cost of cancer treatment could become more manageable for thousands of patients across India following a major decision by the central government. The Centre has capped trade margins on non-scheduled anti-cancer medicines at 30% of their Maximum Retail Price (MRP), aiming to curb excessive mark-ups and make essential medicines more affordable.
According to government estimates, the move could reduce the prices of certain cancer medicines by as much as 70% and help patients save approximately ₹2,500 crore every year. However, the actual reduction will depend on the medicines covered under the policy and the trade margins currently applied to them.
The decision is particularly significant for patients who depend on expensive medicines for prolonged periods. By extending price protection to a broader range of anti-cancer drugs, the government aims to reduce out-of-pocket healthcare expenses and improve access to treatment.
Which Cancer Medicines Will Be Covered Under the New Rule?
The new measure is intended to cover non-scheduled anti-cancer medicines across several categories. Both branded and generic drugs, along with domestically manufactured and imported medicines, are expected to fall within its scope. Patented and non-patented cancer medicines will also be covered under the proposed framework.
The policy focuses on limiting the trade margins added at different stages of the medicine supply chain, including distribution and retail sales. This could help address situations where the difference between a medicine’s purchase cost and its retail price becomes particularly high.
An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines covered by the measure. The National Pharmaceutical Pricing Authority (NPPA) will then issue the required notification.
The final list will determine which medicines receive the additional price protection and how widely patients benefit from the decision.
How Much Could Cancer Patients Save?
The Centre estimates that the initiative could generate annual savings of around ₹2,500 crore for cancer patients. Some medicines could become up to 70% cheaper, although this reduction will not necessarily apply to every drug.
The financial benefit will depend on existing trade margins, the medicine’s current MRP and whether it is included in the final list.
Cancer treatment often involves several expenses, including chemotherapy, radiation therapy, surgery, diagnostic tests and follow-up consultations. For patients requiring long-term medication, the recurring cost of drugs can put considerable pressure on family budgets.
The new cancer drug price cap aims to reduce this financial burden by limiting the margins charged across the supply chain. If implemented effectively, it could make selected medicines more accessible and help patients manage their treatment expenses.
However, patients should check the revised prices of their prescribed medicines after the official notification rather than assume that all cancer drugs will become 70% cheaper.
Scheduled vs Non-Scheduled Medicines: What Is the Difference?
India’s drug pricing framework distinguishes between scheduled and non-scheduled medicines under the Drugs (Prices Control) Order, 2013 (DPCO).
Scheduled Medicines
Scheduled medicines are included in Schedule I of the DPCO and are subject to government price regulation. The NPPA can establish ceiling prices for these drugs, and manufacturers must comply with the applicable limits.
Non-Scheduled Medicines
Non-scheduled medicines fall outside the scheduled list and are not governed by the same ceiling-price mechanism. Under the existing framework, manufacturers are generally restricted from increasing their maximum retail prices by more than 10% during the preceding 12 months.
The latest measure seeks to introduce an additional safeguard for non-scheduled anti-cancer medicines by restricting their trade margins to 30% of MRP. This approach is intended to address excessive mark-ups and improve affordability for patients.
Government Previously Introduced Cancer Drug Price Controls in 2019
The Centre has taken similar steps in the past to control the prices of selected cancer medicines.
In February 2019, the NPPA introduced a 30% trade margin cap on 42 selected non-scheduled anti-cancer medicines. Government figures indicated that the intervention reduced the prices of 526 medicine brands by approximately 50% and generated estimated annual savings of ₹984 crore for patients.
The latest decision seeks to expand this approach to a wider range of non-scheduled anti-cancer medicines. By extending the coverage, the government aims to address excessive price mark-ups across more categories of cancer treatment.
also read:- 9 October 2026 Panchang: Tithi, Shubh Muhurat, Rahukaal,…
The earlier initiative provides context for the current move, although the final impact of the expanded policy will depend on its implementation and the medicines included.
Why Is the New Cancer Drug Price Cap Important?
Cancer treatment continues to be a significant financial challenge for many Indian households. The burden can be especially severe when patients require expensive medicines over several months or years.
Although government price controls already apply to scheduled medicines, some non-scheduled drugs can remain costly. Large differences between the procurement cost and the final retail price can further increase patients’ expenses.
The cancer drug price cap is intended to narrow these differences by restricting trade margins and improving price transparency. The measure could offer meaningful financial relief to patients who rely on medicines included in the final list.
The government has also stated that manufacturers will be required to maintain existing production levels to help ensure that medicines covered by the policy remain available in the market.
Maintaining adequate supplies will be important because lower prices can benefit patients only when prescribed medicines are consistently accessible.
When Will Patients See the Benefits?
The next important step is the finalisation of the list of eligible medicines by the expert committee under the DGHS, followed by the necessary notification from the NPPA.
Once the relevant details are officially notified and implemented, patients will be able to determine whether their prescribed medicines are covered and what price changes apply.
The cancer drug price cap could represent a major step towards making treatment more affordable, with estimated annual savings of ₹2,500 crore. However, the extent of relief will vary depending on the medicine and its existing trade margins.
For patients and their families, the key takeaway is to look for the official revised prices rather than expect a uniform reduction across all cancer medicines. The success of the initiative will ultimately depend on effective implementation, transparent pricing and the continued availability of essential drugs.
For More Hindi News: http://newz24india.com